Advertising
Showing 1 to 15 of 17 entries
BUY on WEAKNESS
Small caps have seen some correction, but the underlying fundamentals are growing. The business continues to move forward. What was considered telemedicine has now extended out to more services, such as employer plans. Top line growth is around 10% per quarter. They are profitable and has large cash positions to make acquisitions. Trading at half the valuation of WELL.
Healthcare
BUY
Exciting play on telemedicine. Entire sector is pricey, but good upside opportunity if the trends continue. The whole concept makes a lot of sense. Good sector to have some exposure to. He owns a small position.
Healthcare
TOP PICK
It is one of the fastest growing healthcare solutions providers. They made a series of very targeted acquisitions which they are integrating. A quality company with quality assets. (Analysts’ price target is $4.19)
Healthcare
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenue grew by 461% year over year. However, EPS missed estimates. It is growing extremely fast and organic growth is forecasted to be driven by partner relationships. The balance sheet is growing rapidly and top-line growth should outpace operating expenses. Unlock Premium - Try 5i Free

Healthcare
DON'T BUY
It was caught up with other health care names when COVID hit. The company got a little ahead of itself with the excitement of remote medicine. They raised a lot of capital and acquired a lot of companies. It is a wait-and-see for him. They need to justify the valuation that it is at now. He prefers others.
Healthcare
TOP PICK
Telemedicine plus they use AI in their medical clinics. They make acquisitions to synergize and they grow organically. They boast $130 in revenue and $50 million in cash, so they can continue to buy more companies. It trades at 2.5x revenue vs.peers at 6x. Expect good multiple appreciation. Managers own a lot of stock and he's known them from the start. They execute well. They should rise a lot higher. (Analysts’ price target is $3.96)
Healthcare
TOP PICK
Healthcare solution providers. Acquisitions and organic growth. Really likes the recent push of one-stop healthcare shopping to employers and insurance companies. Sector has come down, waiting for two deals to close, trading at 3x profitable revenues. Great opportunity. No dividend. (Analysts’ price target is $3.96)
Healthcare
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It reported strong revenue growth at $8.8M. An increase of 187% YoY. They made 5 acquisitions and is well-capitalized to pursue more. There is also organic growth in all parts of the business. Long term outlook looks good. Unlock Premium - Try 5i Free

Healthcare
DON'T BUY
Loss of 2 cents this year, gain of 2 cents next year. Telemedicine is a fantastic opportunity, but not a lot of barriers to entry, and the big guys are already involved. He favours companies with high barriers to entry. PE of 100, so he'd pass.
Healthcare
PAST TOP PICK
(A Top Pick Apr 27/20, Up 282%) Tele-medicine. Expanded through Canada and now into US. Trading at lower valuation than peers. Just raised capital for more acquisitions of technology and clinics.
Healthcare
BUY on WEAKNESS
They are doing a lot of interesting things. He decided to take a position in another in the space. The problem was the valuation. It is too expensive. It is a promising space in the long run. It is expensive right now but a well managed company. You need to buy it cheaply and smartly.
Healthcare
BUY
It's in the hot telemedicine sector. This was a former top pick. Has done very well this year. They've built their platform this year. They've done a deal with pharmacies in the west, and have bought companies in tech and physical clinics. This will give their customers a choice between e-contacting a doctor and meeting one in person, or doing both. Vaccine needs is pressuring e-health stocks, but he expects this to continue growing.
Healthcare
BUY

WELL Health vs. Cloud MD, and buy the warrants? Different companies in the same sector. He owns both and expects both to excel in the coming year. Cloud MD just released earnings, not as strong as he expected, but talked about future catalysts coming in the fall. WELL just announced an acquisition and got financing from their biggest shareholder, Lee Ka-Shing. Both are equally good. Warrants: you could do this, but the challenge is that both stocks have enjoyed huge runs and profit-taking could happen. You have a finite time before those warrants expire worthless or you decide to exercise the warrants--it's riskier, though offers a higher return. In contrast, you can just hold onto the stock.

Healthcare
BUY
They should be able to capitalize well on the COVID trend and then the telemedicine trend that will go on. CloudMD has an interesting platform. The stock has not done much in the last 6 weeks. They completed a financing. He suspects people were subscribing and then selling the stock and holding the warrant. He thinks it will continue to do well over the next two years.
Healthcare
WATCH
Tele-medicine? He likes this space. When they looked at what sectors will benefit post-pandemic, this was one. PM Trudeau has committed to putting government money into this space. What worries him about Canadian holdings, is that they are small fish in a big pond. Other companies already have over 50 million subscribers. Valuations are pretty stretched, so he would watch for good opportunities.
Healthcare
Showing 1 to 15 of 17 entries

CloudMD(DOC-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 9

Stockchase rating for CloudMD is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CloudMD(DOC-X) Frequently Asked Questions

What is CloudMD stock symbol?

CloudMD is a Canadian stock, trading under the symbol DOC-X on the TSX Venture Exchange (DOC-CV). It is usually referred to as TSXV:DOC or DOC-X

Is CloudMD a buy or a sell?

In the last year, 9 stock analysts published opinions about DOC-X. 7 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for CloudMD.

Is CloudMD a good investment or a top pick?

CloudMD was recommended as a Top Pick by on . Read the latest stock experts ratings for CloudMD.

Why is CloudMD stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CloudMD worth watching?

9 stock analysts on Stockchase covered CloudMD In the last year. It is a trending stock that is worth watching.

What is CloudMD stock price?

On 2021-10-19, CloudMD (DOC-X) stock closed at a price of $1.59.